Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INCCCEL · Entity 7400 | Director | October 21, 2025 | October 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRYO CELL INTERNATIONAL INC
Report date October 21, 2025 · Filed October 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2035-10-21 | Direct | 5,300 |
Reported balance
After 2025-10-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-21 · Grant · Acquired 5,300 · Balance 5,300 F1: Stock options vest at a rate of 1/12 per month commencing on October 21, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.63 · Expires 2031-10-20 | Direct | 5,300 |
Reported balance
Holding disclosure · report date 2025-10-21 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 5,300 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2032-10-03 | Direct | 5,300 |
Reported balance
Holding disclosure · report date 2025-10-21 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,300 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2033-10-10 | Direct | 5,300 |
Reported balance
Holding disclosure · report date 2025-10-21 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 5,300 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2034-10-29 | Direct | 5,300 |
Reported balance
Holding disclosure · report date 2025-10-21 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 5,300 |
| Common StockSEC Table I · non-derivative | Direct | 30,634 |
Reported balance
Holding disclosure · report date 2025-10-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 30,634 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest at a rate of 1/12 per month commencing on October 21, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 21, 2025 Filed Oct 23, 2025 21:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 5,300 | $4.35 Strike: $4.35 | $23,055.00 |
DisclosureSEC source: 0001193125-25-248885 · ownership.xml · derivative · entry 6 Mizrahi Daniel · CIK 0001888345 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2035-10-21 F1 · derivative.exercise_date: Stock options vest at a rate of 1/12 per month commencing on October 21, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.